TITLE

Targeting Tat and IFNα as a Therapeutic AIDS Vaccine

AUTHOR(S)
Gallo, R.C.; Burny, A.; Zagury, D.
PUB. DATE
September 2002
SOURCE
DNA & Cell Biology;Sep2002, Vol. 21 Issue 9, p611
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Evolution to AIDS is characterized by a progressive cellular immune suppression. Although there is substantial evidence for several mechanisms involved in disrupting the immune response by induction of apoptosis in responder cells by contact with infected cells, we propose that humoral factors also play a role, and that one such factor is the extracellular form of the human immunodeficiency virus (HIV)-1 Tat protein and another is IFNα. Both Tat and interferon-α (IFNα) inhibit antigen-stimulate T-cell proliferation, and specific anti-Tat and/or anti-IFNα Abs prevent generation of HIV-1-induced suppressor cells. We propose that high titer anti-Tat and/or anti-IFNα Abs, neutralizing extracellular Tat, and/or IFNα, induced by vaccines described here, antagonize HIV-1-induced immunosuppression. Innocuous vaccines were prepared by using inactivated but immunogenic Tat (Toxoid) and inactivated and immunogenic IFNα (kinoid) derivatives. Both Tat Toxoid and IFNα kinoid were well tolerated and elicited specific neutralizing antibodies (Abs) in mice, monkeys, and seronegative and HIV-1-infected individuals.
ACCESSION #
7411863

 

Related Articles

  • Induction of immune responses to a human immunodeficiency virus type 1 epitope by novel chimeric influenza viruses. Takizawa, Naoki; Morita, Mayuko; Adachi, Kei; Watanabe, Ken; Kobayashi, Nobuyuki // Drug Discoveries & Therapeutics;Dec2009, Vol. 3 Issue 6, p252 

    Mucosal and systemic immune responses play an important role in the prevention of infections, including infection with human immunodeficiency virus type 1 (HIV-1). Influenza virus can efficiently induce mucosal and systemic immune responses, and thus, chimeric influenza viruses expressing the...

  • Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. Pernas, Mar�a; Casado, Concepci�n; Arcones, Carolina; Llano, Anuska; S�nchez-Merino, V�ctor; Mothe, Beatriz; Vicario, Jos� L.; Grau, Eulalia; Ruiz, Lidia; S�nchez, Jorge; Telenti, Amalio; Yuste, Elo�sa; Brander, Christian; L�pez- Gal�ndez, Cecilio // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objective: To study the causes for the lack of clinical progression in a superinfected HIV-1 LTNP elite controller patient. Methodology and Principal Findings: We studied host genetic, virological and immunological factors associated with viral control in a SI long term non progressor elite...

  • Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. Pernas, María; Casado, Concepción; Arcones, Carolina; Llano, Anuska; Sánchez-Merino, Víctor; Mothe, Beatriz; Vicario, José L.; Grau, Eulalia; Ruiz, Lidia; Sánchez, Jorge; Telenti, Amalio; Yuste, Eloísa; Brander, Christian; López- Galíndez, Cecilio // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objective: To study the causes for the lack of clinical progression in a superinfected HIV-1 LTNP elite controller patient. Methodology and Principal Findings: We studied host genetic, virological and immunological factors associated with viral control in a SI long term non progressor elite...

  • Persistence of Human Immunodeficiency Virus (HIV) Type 1 DNA in Peripheral Blood Despite Prolonged Suppression of Plasma HIV-1 RNA in Children. Saitoh, Akihiko; Hsia, Karen; Fenton, Terence; Powell, Christine A.; Christopherson, Cindy; Fletcher, Courtney V.; Starr, Stuart E.; Spector, Stephen A. // Journal of Infectious Diseases;5/15/2002, Vol. 185 Issue 10, p1409 

    Examines the persistence of HIV type 1 DNA in peripheral blood mononuclear cells in children. Usefulness of HIV-1 DNA as a marker for virus suppression; Effect of antiretroviral therapy on HIV-1 DNA levels; Median half-life of intracellular HIV-1 DNA.

  • Bug of the Month. Taylor, Sue // Geographical (Campion Interactive Publishing);Apr99, Vol. 71 Issue 4, p59 

    Focuses on human immunodeficiency virus (HIV). How the disease is transmitted; Symptoms of HIV.

  • Frequent Detection of Human Adenovirus from the Lower Gastrointestinal Tract in Men Who Have Sex with Men. Curlin, Marcel E.; Meei-Li Huang; Xiaoyan Lu; Celum, Connie L.; Sanchez, Jorge; Selke, Stacy; Baeten, Jared M.; Zuckerman, Richard A.; Erdman, Dean D.; Corey, Lawrence // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    Background: The association between baseline seropositivity to human adenovirus (HAdV) type 5 and increased HIV acquisition in the Step HIV Vaccine Study has raised questions concerning frequency of acquired and/or persistent Adenovirus infections among adults at high risk of HIV-1 infection....

  • Efficacy of Induction Therapy with High-Dose Interferon for Patients with Hemophilia and Human Immunodeficiency Virus-Hepatitis C Virus Coinfection. Hanabusa, Hideji // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p1527 

    To evaluate the efficacy of high-dose interferon (IFN) on human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, 15 HIV-positive patients and 15 age-matched HIV-negative patients with hemophilia were treated with 9 million units (MU) of IFN-α2a daily for 2 weeks, followed...

  • Human immune response may be pivotal for future HIV vaccines. Volansky, Rob // Infectious Disease News;Oct2008, Vol. 21 Issue 10, p35 

    The article discusses research being done on the link between human immune response and human immunodeficiency virus (HIV) vaccines. It references a study Alan Bernstein, presented at the XVII International AIDS Conference held in August 2008. Bernstein claimed that the interactions between...

  • Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV-1 Infection. Juliana McElrath, M. // Journal of Infectious Diseases;10/15/2010 Primary HIV-1 Infection, Vol. 202, pS323 

    Unanticipated results from 2 recent candidate human iinmunodeficiency virus type 1 (HIV-1) vaccine regimens in large-scale international trials highlight the importance of understanding the optimal earliest immune defense against HIV-1 infection. Presented here are key findings in these vaccine...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics